Compare · IRIX vs ITGR
IRIX vs ITGR
Side-by-side comparison of IRIDEX Corporation (IRIX) and Integer Holdings Corporation (ITGR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRIX and ITGR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- ITGR is the larger of the two at $3.10B, about 157.7x IRIX ($19.7M).
- Over the past year, IRIX is up 16.0% and ITGR is down 23.2% - IRIX leads by 39.2 points.
- ITGR has been more active in the news (16 items in the past 4 weeks vs 10 for IRIX).
- ITGR has more recent analyst coverage (23 ratings vs 0 for IRIX).
- Company
- IRIDEX Corporation
- Integer Holdings Corporation
- Price
- $1.13+0.90%
- $92.19+0.94%
- Market cap
- $19.7M
- $3.10B
- 1M return
- +7.66%
- +8.28%
- 1Y return
- +15.98%
- -23.19%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 1996
- News (4w)
- 10
- 16
- Recent ratings
- 0
- 23
IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Integer Holdings Corporation
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Latest IRIX
- Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
- Chief Financial Officer Dizon Romeo R bought $2,688 worth of shares (2,400 units at $1.12), increasing direct ownership by 2% to 133,325 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $2,899 worth of shares (2,521 units at $1.15), increasing direct ownership by 2% to 130,925 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $2,808 worth of shares (2,400 units at $1.17), increasing direct ownership by 2% to 128,404 units (SEC Form 4)
- SEC Form SD filed by IRIDEX Corporation
- President and CEO Mercer Patrick covered exercise/tax liability with 19,233 shares, decreasing direct ownership by 5% to 372,774 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $5,004 worth of shares (5,004 units at $1.00), increasing direct ownership by 4% to 126,004 units (SEC Form 4)
- SEC Form 10-Q filed by IRIDEX Corporation
- IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Iridex Reports First Quarter 2026 Financial Results
Latest ITGR
- Integer to Participate in Truist Securities 2026 MedTech Conference on June 16
- Director Maxwell Martin C was granted 1,967 shares, increasing direct ownership by 9% to 25,106 units (SEC Form 4)
- SEC Form 4 filed by Director Hinrichs James F.
- Director Coyle Michael J was granted 1,967 shares, increasing direct ownership by 145% to 3,322 units (SEC Form 4)
- Director Kapito Aaron was granted 1,967 shares, increasing direct ownership by 144% to 3,338 units (SEC Form 4)
- Director Capps Cheryl C was granted 1,967 shares, increasing direct ownership by 17% to 13,669 units (SEC Form 4)
- Director Jeffers Alvin Tyrone was granted 1,967 shares, increasing direct ownership by 76% to 4,552 units (SEC Form 4)
- Director Antrum Sheila was granted 1,967 shares, increasing direct ownership by 19% to 12,069 units (SEC Form 4)
- Director Passerini Filippo was granted 1,967 shares, increasing direct ownership by 7% to 31,114 units (SEC Form 4)
- Director Flanagan James Francis was granted 1,967 shares, increasing direct ownership by 480% to 2,377 units (SEC Form 4)